Kymera
Eczema drug Kymera succeeds in first trial, could rival Dupixent
Kymera Therapeutics announced Monday that, for the second time this year, it had successfully completed an early trial of a closely watched drug intended to rival Sanofi and Regeneron’s blockbuster treatment Dupixent. The phase 1 BroADen study enrolled 22 patients with moderate to severe eczema (atopic dermatitis), all of whom took Kymera’s investigational pill, KT-621. […]
1 min read